Moderate ResearchSexual Health

Prostamax

KEDP

KEDP Tetrapeptide | Prostate Bioregulator

Half-life

Not established

Chain length

4 amino acids

Reference frequency

Daily for 10-20 days per cycle

Research overview

DoseGear research brief

Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.

Mechanism of action

Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Khavinson-associated prostate bioregulator peptide.

What it is researched for

Experimental prostate tissue regulation through proposed gene-expression and proliferation effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Prostate cancer (consult oncologist)
Known hypersensitivity
Pregnancy (not applicable)

Scientific references

01
Experimental Studying of Drug Efficiency Prostamax in Therapy of Chronic Aseptic Prostatitis
Scientific citationExperimental Studying of Drug Efficiency Prostamax in Therapy of Chronic Aseptic Prostatitis. Bulletin of Experimental Biology and Medicine (2013).
02
Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects
Scientific citationEffects of Short Peptides on Lymphocyte Chromatin in Senile Subjects. Bulletin of Experimental Biology and Medicine (2004).
03
Deheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator (Lys-Glu-Asp-Pro)
Scientific citationDeheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator (Lys-Glu-Asp-Pro). Georgian Medical News (2012).
04
Khavinson Peptide Bioregulators
Scientific citationKhavinson Peptide Bioregulators. Advances in Gerontology (2020).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Sexual Health